Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda

Journal of Infectious Diseases

Volumn 197, Issue 11, 2008, Pages 1598-1604

  Lynch, Caroline ^a   Pearce, Richard ^a   Pota, Hirva ^a   Cox, Jonathan ^a   Abeku, Tarekegn A ^a   Rwakimari, John ^b   Naidoo, Inbarani ^a,c   Tibenderana, James ^a   Roper, Cally ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MINISTRY OF HEALTH   (Uganda)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; FANSIDAR; FOLIC ACID ANTAGONIST;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DHFR GENE; DHPS GENE; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MUTATOR GENE; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; UGANDA;

ADOLESCENT; ADULT; ANIMALS; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; HAPLOTYPES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MUTATION, MISSENSE; PLASMODIUM FALCIPARUM; TETRAHYDROFOLATE DEHYDROGENASE; UGANDA;

EID: 43949128393     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587845     Document Type: Article

References (65)

1. Wilairatana P, Kyle DE, Looareesuwan S, et al. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute uncomplicateds falciparum malaria in Thailand. Ann Trop Med Parasitol 1997; 91:125-32.
2. Krudsood S, Imwong M, Wilairatana P, et al. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Trans R Soc Trop Med Hyg 2005; 99:142-9.
3. Nzila A, Ochong E, Nduati E, et al. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans Roy Soc Trop Med Hyg 2005; 99:341-6.
4. Hastings MD, Bates SJ, Blackstone EA, Monks SM, Mutabingwa TK, Sibley CH. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg 2002; 96:674-6.
5. McCollum AM, Poe AC, Hamel M. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis 2006; 194:189-97.
6. Farnert A, Tengstam K, Palme IB, et al. Polyclonal Plasmodium falciparum malaria in travellers and selection of antifolate mutations after proguanil prophylaxis. Am J Trop Med Hyg 2002; 66:487-91.
7. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ. Relationship between age, molecular markers and response to sulphadoxine- pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health 2004; 9:624-9.
8. Alker AP, Mwapasa V, Purfield A, et al. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother 2005; 49:3919-21.
9. Menard D, Djalle D, Yapou F, Manirakiza A, Talarmin A. Frequency distribution of antimalarial drug-resistant alleles among isolates of Plasmodium falciparum in Bangui, Central African Republic. Am J Trop Med Hyg 2006; 74:205-10 [erratum: Am J Trop Med Hyg 2006; 74:516].
10. Francis D, Nsobya SL, Talisuna A, et al. Geographic differences in antimalarial efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 2006; 193:978-86.
11. Abeku TA, Hay SI, Ochola S, et al. Malaria epidemic early warning and detection in African highlands. Trends Parasitol 2004; 20:400-5.
12. Ministry of Health. Statistical abstract. Kampala, Uganda: Ministry of Health Resource Centre, 2002. Available at: http://www.health.go.ug/docs/ abstract2001.pdf. Accessed 22 April 2008.
13. Pearce R, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother 2003; 47:1347-54.
14. Roper C, Pearce R, Bredenkamp B, et al. Antifolate antimalarial resistance in southeast Africa. Lancet 2003; 361:1174-81.
15. Nair S, Williams JT, Brockman A, et al. A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol Biol Evol 2003; 20:1526-36.
16. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine resistant malaria. Science 2004; 305:1124.
17. Ndiaye D, Daily JP, Sarr O, et al. Defining the origin of Plasmodium falciparum resistant dhfr isolates in Senegal. Acta Tropica 2006; 99:106-11.
18. Maïga AA, Djimdé V, Hubert E, et al. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J Infect Dis 2007; 196:165-72.
19. Hyde JE. Exploring the folate pathway in Plasmodium falciparum. Acta Tropica 2005; 94:191-206.
20. Wang P, Wang Q, Sims PFG, Hyde JE. Characterisation of exogenous folate transport in Plasmodium falciparum. Mol Biochem Parasitol 2007; 154:40-51.
21. Volkman SK, Sabeti PC, Decaprio D, et al. A genome-wide map of diversity in Plasmodium falciparum. Nat Genet 2007; 39:113-9.
22. A-Elbasit IE, Alifrangis M, Khalil IF, et al. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics. Malar J 2007; 6:108.
23. Anderson TJ, Nair S, Jacobzone C, Zavai A, Balkan S. Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province, Sudan. Trop Med Int Health 2003; 8:1068-73.
24. Basco LK, Ndounga M, Tejiokem M, et al. Molecular epidemiology of malaria in Cameroon. XI. Geographic distribution of Plasmodium falciparum isolates with dihydrofolate reductase gene mutations in southern and central Cameroon. Am J Trop Med Hyg 2002; 67:378-82.
25. Basco LK, Tahar R, Keundjian A, Ringwald P. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis 2000; 182:624-8.
26. Basco LK, Tahar R, Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother 1998; 42:1811- 4.
27. Berzosa PJ, Puente S, Benito A. Malaria cure with sulphadoxine/ pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes. Parasitol Res 2005; 97:287-9.
28. Bwijo B, Kaneko A, Takechi M, et al. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop 2003; 85:363-73.
29. Curtis J, Duraisingh MT, Warhurst DC. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J Infect Dis 1998; 177:1429-33.
30. Diourte Y, Djimde A, Doumbo OK, et al. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg 1999; 60:475-8.
31. Djaman JA, Mazabraud A, Basco L. Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Cote d'Ivoire. Ann Trop Med Parasitol 2007; 101:103-12.
32. Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg 2006; 75:162-5.
33. Doumbo OK, Kayentao K, Djimde A, et al. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J Infect Dis 2000; 182:993-6.
34. Eberl KJ, Jelinek T, Aida AO, et al. Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania. Trop Med Int Health 2001; 6:756-60.
35. Fernandes N, Figueiredo P, do Rosario VE, Cravo P. Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant. Malar J 2007; 6:35.
36. Gebru-Woldearegai T, Hailu A, Grobusch MP, Kun JF. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg 2005; 73:1131-4.
37. Hamour S, Melaku Y, Keus K, et al. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Trans R Soc Trop Med Hyg 2005; 99:548-54.
38. Happi CT, Gbotosho GO, Folarin OA, et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop 2005; 95:183-93.
39. Jelinek T, Kilian AH, Kabagambe G, von Sonnenburg F. Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. Am J Trop Med Hyg 1999; 61:463-6.
40. Jelinek T, Kilian AH, Westermeier A, et al. Population structure of recrudescent Plasmodium falciparum isolates from western Uganda. Trop Med Int Health 1999; 4:476-80.
41. Jelinek T, Ronn AM, Lemnge MM, et al. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Trop Med Int Health 1998; 3:605-9.
42. Jelinek T, Ronn AM, Curtis J, et al. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/ pyrimethamine resistance. Trop Med Int Health 1997; 2:1075-9.
43. Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg 2003; 68:586-9.
44. Khalil I, Alifrangis M, Ronn AM, et al. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. Am J Trop Med Hyg 2002; 67:225-9.
45. Khan B, Omar S, Kanyara JN, et al. Antifolate drug resistance and point mutations in Plasmodium falciparum in Kenya. Trans R Soc Trop Med Hyg 1997; 91:456-60.
46. Malamba SS, Mermin J, Reingold A, et al. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg 2006; 75:375-80.
47. Mbugi EV, Mutayoba BM, Malisa AL, Balthazary ST, Nyambo TB, Mshinda H. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malar J 2006; 5:94.
48. Mockenhaupt FP, Teun Bousema J, Eggelte TA, et al. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health 2005; 10:901-8.
49. Mugittu K, Ndejembi M, Malisa A, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 2004; 71:696-702.
50. Mutabingwa T, Nzila A, Mberu E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001; 358:1218-23.
51. Ndiaye D, Daily JP, Sarr O, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop Med Int Health 2005; 10:1176-9.
52. Ndounga M, Tahar R, Basco LK, Casimiro PN, Malonga DA, Ntoumi F. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo. Trop Med Int Health 2007; 12:1164-71.
53. Nkhoma S, Molyneux M, Ward S. Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Trop 2007; 102:138-42.
54. Nzila AM, Mberu EK, Sulo J, et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000; 44:991-6.
55. Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 1998; 42:164-9.
56. Ochong E, Nzila A, Kimani S, et al. Molecular monitoring of the Leu-164 mutation of dihydrofolate reductase in a highly sulfadoxine/pyrimethamine- resistant area in Africa. Malar J 2003; 2:46.
57. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 2001; 95:315-9.
58. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176:1590-6.
59. Sendagire H, Kaddumukasa M, Ndagire D, et al. Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Trop 2005; 95:172-82.
60. Schonfeld M, Barreto Miranda I, Schunk M, et al. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malar J 2007; 6:2.
61. Tahar R, Basco LK. Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. Am J Trop Med Hyg 2006; 75:396-401.
62. Tahar R, Basco LK. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children. Acta Trop 2007; 103:81-9.
63. van den Broek IV, Gatkoi T, Lowoko B, Nzila A, Ochong E, Keus K. Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan. Trans R Soc Trop Med Hyg 2003; 97:229-35.
64. Wang P, Lee CS, Bayoumi R, et al. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 1997; 89:161-77.
65. Wilson PE, Kazadi W, Alker AP, Meshnick SR. Rare Congolese Plasmodium falciparum DHFR alleles. Mol Biochem Parasitol 2005; 144:227-9.